We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+22.55%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$69.3M
(+11%)
Cap. Flow
+$84.1M
Cap. Flow
% of AUM
12.38%
Top 10 Holdings %
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4
Top Buys
| 1 |
Structure Therapeutics
GPCR
|
+$37.1M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$36.6M |
| 3 |
Savara
SVRA
|
+$35.7M |
| 4 |
CMPS
Compass Pathways
CMPS
|
+$34.2M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$20.8M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$96.3M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$52.9M |
| 3 |
Immunovant
IMVT
|
+$7.23M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$5.49M |
| 5 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$2.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Structure Therapeutics
GPCR
$3.27B
| $75.8M | 11.16% |
1,502,747
+1,152,747
| +329% | +$37.1M |
|
2
Cogent Biosciences
COGT
$6.48B
| $54.9M | 8.08% |
5,631,042
| – | – |
|
3
Geron
GERN
$911M
| $49.6M | 7.3% |
23,375,839
-213,940
| -0.9% | -$581K |
|
4
AN2 Therapeutics
ANTX
$168M
| $43.1M | 6.34% |
2,678,209
+1,388,889
| +108% | +$15.7M |
|
|
5
Savara
SVRA
$1.13B
| $37.8M | 5.57% |
+10,000,000
| New | +$35.7M |
|
|
6
Taysha Gene Therapies
TSHA
$1.72B
| $35.1M | 5.17% |
+11,111,111
| New | +$20.8M |
|
|
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
| $32.7M | 4.81% |
3,395,495
| – | – |
|
|
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $32.1M | 4.73% |
+1,750,387
| New | +$36.6M |
|
|
JBIO
9
Jade Biosciences
JBIO
$1.25B
| $29.9M | 4.4% |
62,894
| – | – |
|
|
ICVX
10
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $28.7M | 4.23% |
3,703,704
| – | – |
|
|
CMPS
11
Compass Pathways
CMPS
$1.68B
| $28.5M | 4.2% |
+3,858,000
| New | +$34.2M |
|
|
VTYX
12
DELISTED
Ventyx Biosciences
VTYX
| $28.3M | 4.17% |
815,724
| – | – |
|
13
Tyra Biosciences
TYRA
$1.88B
| $27.4M | 4.03% |
1,989,103
| – | – |
|
14
Madrigal Pharmaceuticals
MDGL
$12.6B
| $26.3M | 3.87% |
179,917
+30,000
| +20% | +$5.65M |
|
|
SLN
15
Silence Therapeutics
SLN
$516M
| $20.7M | 3.04% |
2,104,875
| – | – |
|
16
Tarsus Pharmaceuticals
TARS
$2.52B
| $20.3M | 2.99% |
+1,142,857
| New | +$20.2M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $19.3M | 2.84% |
+869,908
| New | +$18.3M |
|
18
Dyne Therapeutics
DYN
$3.76B
| $14.8M | 2.18% |
1,650,150
| – | – |
|
|
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
| $13.2M | 1.94% |
+2,040,816
| New | +$14M |
|
20
Kura Oncology
KURA
$967M
| $13M | 1.91% |
1,423,642
| – | – |
|
|
21
Immunovant
IMVT
$8B
| $12.9M | 1.89% |
334,853
-320,000
| -49% | -$7.23M |
|
22
Entrada Therapeutics
TRDA
$267M
| $9.24M | 1.36% |
584,955
| – | – |
|
|
GRCL
23
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $8.75M | 1.29% |
+3,038,889
| New | +$11.1M |
|
24
Cabaletta Bio
CABA
$435M
| $7.41M | 1.09% |
486,795
| – | – |
|
|
MRUS
25
DELISTED
Merus
MRUS
| $7.07M | 1.04% |
300,000
| – | – |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC